The U.S. Food and Drug Administration has approved Bristol Myers Squibb's Cobenfy (xanomeline and trospium chloride), a first ...
New framework introduces comprehensive guidelines for assessing side effects in psychedelic-assisted therapies, aiming to ...
The Trump administration is expected to liberalise research into psychedelic-assisted therapies – and Emyria investors have ...
PsyPost on MSN6d
Relaxation — not mystical experiences — emerges as best predictor of psychedelic therapy’s impact in surprising new studyA recent study published in the Journal of Psychopharmacology examined the effectiveness of psychedelic-assisted therapy on ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback